Dean Capital Investments Management LLC Acquires New Position in Evelo Biosciences Inc (EVLO)

Dean Capital Investments Management LLC acquired a new position in Evelo Biosciences Inc (NASDAQ:EVLO) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 36,924 shares of the company’s stock, valued at approximately $436,000.

Separately, Essex Investment Management Co. LLC purchased a new stake in Evelo Biosciences in the second quarter worth about $271,000. 0.54% of the stock is owned by institutional investors and hedge funds.

EVLO has been the subject of a number of research reports. Morgan Stanley started coverage on shares of Evelo Biosciences in a research note on Monday, June 4th. They issued an “overweight” rating for the company. Cowen started coverage on shares of Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating for the company. BMO Capital Markets started coverage on shares of Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, JMP Securities started coverage on shares of Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating and a $25.00 target price for the company.

Shares of Evelo Biosciences stock opened at $13.22 on Tuesday. The company has a quick ratio of 24.08, a current ratio of 24.08 and a debt-to-equity ratio of 0.09. Evelo Biosciences Inc has a one year low of $11.10 and a one year high of $16.75.

Evelo Biosciences (NASDAQ:EVLO) last announced its earnings results on Thursday, August 2nd. The company reported ($0.85) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.49). equities analysts predict that Evelo Biosciences Inc will post -1.88 EPS for the current year.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.

See Also: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding EVLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evelo Biosciences Inc (NASDAQ:EVLO).

Institutional Ownership by Quarter for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply